Some cancers, like blood cancers, tend to be highly sensitive to CD47 signaling blocking therapies but not to CD24 signaling inhibitors, while others, such as ovarian cancer, are more responsive to CD24 signaling blocking therapies. This evidence concerns the gene CD24 and ovarian cancer.